Covid-19 roundup: AstraZeneca resumes vaccine trials in Japan; Global lab network is established to compare Covid-19 vaccines
AstraZeneca has resumed trials of its Oxford University-developed Covid-19 vaccine in Japan, while US testing remains on hold.
The trials screeched to a halt earlier this month, after a British participant developed what’s believed to be transverse myelitis, a spinal inflammatory disorder.
While the UK, Brazil, India and South Africa have allowed testing to continue, the US is taking a deeper look into the potentially severe adverse event. The FDA has requested to see trial data for similar vaccines developed by Oxford University researchers, unnamed sources told Reuters.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.